Insights from CARTITUDE-4 and KarMMa-3 in R/R MM
Experts on multiple myeloma provide their impressions of the CARTITUDE-4 and KarMMa-3 studies, which led to the approval of cilta-cel and ide-cel in earlier lines of treatment for patients with relapsed/refractory disease.
EP: 1.The Rationale for CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
EP: 2.The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment
EP: 3.How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment
EP: 4.Key Takeaways from the CARTITUDE-1 and KarMMa Studies
EP: 5.CAR T-Cell Therapy in R/R MM: Treatment Selection, Safety, and Future Perspectives
Now Viewing
EP: 6.Insights from CARTITUDE-4 and KarMMa-3 in R/R MM
EP: 7.Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM
Video content above is prompted by the following questions:
- Briefly review the CARTITUDE-4 trial that led to cilta-cel’s approval in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM).
- Please comment on the patient population – intention-to-treat vs patients treated.
- What was the rationale for the difference? How does it affect your interpretation of the data?
- How did the safety outcomes compare with other CARTITUDE trials?
- Please share your real-world experience.
- Please review data from KarMMa-3, which led to ide-cel’s approval in earlier lines of therapy for R/R MM.
- What are thoughts on the efficacy and safety outcomes?
- Please share your real-world experience.
- How do these approvals impact the current and future treatment landscape of R/R MM?
- How might you choose one over the other?
- How does it address an unmet need?
Recent Videos
Related Content
